Clinical colorectal cancer: "2008 - the year in review"

Clinical Colorectal Cancer

Volumn 8, Issue 1, 2009, Pages 9-10

  Chu, Edward ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PANITUMUMAB;

ADD ON THERAPY; CANCER CHEMOTHERAPY; CANCER RESEARCH; COLORECTAL CANCER; DRUG EFFICACY; EDITORIAL; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE K RAS; ONCOLOGY; PREDICTION; TREATMENT OUTCOME;

EID: 61349100661     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2009.n.001     Document Type: Editorial

References (4)

1. Van Cutsem E, Lang I, D'Haens G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol 2008; 26(15 suppl):5s (Abstract 2).
2. Bokemeyer C, Bondarenko I, Hartmann JT, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer with FOLFOX with or without cetuximab: The OPUS experience. J Clin Oncol 2008; 26(15 suppl):178s (Abstract 4000).
3. Bokeymeyer C, Bonadarenko I, Makhson A, et al. Cetuximab plus 5-FU/FA/oxali-plaint (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. J Clin Oncol 2007; 25(15 suppl):186s (Abstract 4035).
4. Punt CJ, Tol J, Rodenburg CJ, et al. Randomized phase III study of capecitabine, oxaliplatin, and bevacizuamb with or without cetuximab in advanced colorec-tal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol 2008; 26(15 suppl):180s (Abstract LBA4011).